Immunomedics Inc
IMMU
IMMU was delisted on the 22nd of October, 2020.
124 hedge funds and large institutions have $440M invested in Immunomedics Inc in 2017 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 15 closing their positions.
140% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 15
99% more capital invested
Capital invested by funds: $221M → $440M (+$219M)
86% more call options, than puts
Call options by funds: $21.2M | Put options by funds: $11.4M
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
14% more funds holding
Funds holding: 109 → 124 (+15)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$40.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$21M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$17.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$21.3M |
| 2 |
O
OrbiMed
New York
|
-$13M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$8.81M |
| 4 |
Millennium Management
New York
|
-$5.26M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JGC
126
J. Goldman & Co
New York
| – | -$3.78M | -746,000 | Closed |
|
|
SCM
127
Sio Capital Management
New York
| – | -$1.86M | -506,978 | Closed |
|
128
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2.56M | -505,422 | Closed |
|
129
Group One Trading
Chicago,
Illinois
| – | -$298K | -58,913 | Closed |
|
|
SM
130
Sabby Management
Miami Beach,
Florida
| – | -$253K | -50,000 | Closed |
|
131
Squarepoint
New York
| – | -$130K | -35,471 | Closed |
|
|
OC
132
Oppenheimer & Co
New York
| – | -$120K | -32,770 | Closed |
|
|
CL
133
CSS LLC
Chicago,
Illinois
| – | -$112K | -22,009 | Closed |
|
134
HSBC Holdings
London,
United Kingdom
| – | -$62K | -16,781 | Closed |
|
|
BFM
135
Boothbay Fund Management
New York
| – | -$68.9K | -13,593 | Closed |
|
|
MFW
136
Meristem Family Wealth
Minnetonka,
Minnesota
| – | -$40K | -10,786 | Closed |
|
|
OTC
137
Opera Trading Capital
Paris,
France
| – | -$18K | -5,000 | Closed |
|
|
LTFS
138
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -200 | Closed |
|
|
TRCT
139
Tower Research Capital (TRC)
New York
| – | -$1K | -142 | Closed |
|
IMMU Hedge Fund Activity: Q1 2017 in Review
124 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q1 2017, worth a combined $440M — up 99% from $221M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new IMMU positions and 15 closed out — a net gain of 21 holders — while 39 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $40.1M. The largest seller was Acuta Capital Partners, cutting an estimated $21.3M.
- 124 institutional investors held Immunomedics Inc (IMMU) as of Q1 2017, up from 109 in Q4 2016.
- Funds reported $440M of Immunomedics Inc stock for Q1 2017, up 99% quarter-over-quarter.
- 36 funds opened new Immunomedics Inc positions in Q1 2017 and 15 closed out, a net change of +21 holders.
- The largest Immunomedics Inc buyer in Q1 2017 was BlackRock, an estimated $40.1M added.
- The largest Immunomedics Inc seller in Q1 2017 was Acuta Capital Partners, an estimated $21.3M sold.
Based on aggregated 13F filings for Q1 2017.